Living with Congenital Adrenal Hyperplasia?
Clinical Trials May Help Explore Potential Treatment Options
Congenital adrenal hyperplasia (CAH) is a group of inherited disorders that affect the adrenal glands and their ability to produce certain hormones, particularly cortisol. The most common form is caused by 21-hydroxylase deficiency (21-OHD), which accounts for approximately 90–99% of CAH cases. 21-OHD is associated with impaired cortisol production and, in some individuals, reduced aldosterone production and excess androgen production.
Classic CAH can be associated with adrenal insufficiency and an increased risk of adrenal crisis, particularly during periods of illness or physiological stress. Hormonal imbalance may also contribute to symptoms related to androgen excess, including acne, excessive hair growth, irregular menstrual cycles, fertility difficulties, and changes in growth or development.
If you or someone you know has classic CAH due to 21-hydroxylase deficiency, Revival Research Institute is conducting Congenital Adrenal Hyperplasia Clinical Trials to evaluate an investigational treatment approach for adults living with this condition.
Are You Eligible to Participate?
To qualify for the Congenital Adrenal Hyperplasia Clinical Trials, participants must:
- Be an adult male or female between 18 and 65 years of age
- Have a medically confirmed diagnosis of classic 21-hydroxylase deficiency CAH
*Additional criteria may apply.
Participation in the Congenital Adrenal Hyperplasia Clinical Trials is free of cost. To learn more or determine whether you may qualify, complete the form below. A member of our research team will contact you to discuss your potential eligibility.
About Congenital Adrenal Hyperplasia Clinical Trials
Living with congenital adrenal hyperplasia can require lifelong hormone management and regular medical monitoring. Classic 21-hydroxylase deficiency can affect cortisol and, in some cases, aldosterone production, while excess adrenal androgen production may contribute to additional symptoms and complications.
Revival Research Institute is conducting a clinical trial for adults living with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The study is designed to evaluate the safety and efficacy of an investigational treatment being studied for CAH.
*All study-related procedures and study treatments are provided at no cost to eligible participants. No insurance is required to participate.
*To take the next step, submit the form above, and our research staff will contact you to determine if you qualify. A brief discussion about your health and medical history may be required.
Get Started
What to Expect?
If you are living with classic CAH due to 21-hydroxylase deficiency, you may qualify for Congenital Adrenal Hyperplasia Clinical Trials exploring potential treatment options. After completing the interest form above, a member of our research team will contact you for a brief pre-screening discussion to determine whether you meet the initial eligibility requirements.
If you qualify, you will be asked to review and sign an Informed Consent Form (ICF). This document explains the study procedures, potential risks, possible benefits, and participant responsibilities before you decide whether to participate.
Once consent is provided, you may be invited to one of Revival Research Institute’s study sites for additional screening evaluations. These assessments may include a physical examination, review of medical history, vital signs, laboratory testing, hormone assessments, and other evaluations required by the study protocol.
Participants who meet all study requirements may be enrolled in the Congenital Adrenal Hyperplasia Clinical Trial. Our team will ensure that you fully understand your participation and what to expect throughout the study duration. You are encouraged to ask questions at any time.
Age
Condition
Location
Congenital Adrenal Hyperplasia: An Inherited Adrenal Disorder
Congenital adrenal hyperplasia is a group of inherited disorders caused by defects in adrenal steroid hormone production. The most common form, 21-hydroxylase deficiency, is caused by pathogenic variants in the CYP21A2 gene and affects the adrenal glands’ ability to produce cortisol efficiently.
Congenital Adrenal Hyperplasia May Affect Hormone Production Through
- Reduced cortisol production
- Reduced aldosterone production in some individuals
- Increased ACTH stimulation
- Increased adrenal androgen production
- Accumulation of steroid hormone precursors
Common Features Associated with Classic 21-Hydroxylase Deficiency Include
- Risk of adrenal crisis, particularly during significant physiological stress
- Excess androgen production
- Acne or increased body hair
- Irregular menstrual cycles in some females
- Changes in growth and pubertal development
- Need for ongoing glucocorticoid management
The presentation and severity of CAH can vary depending on the specific form and degree of enzyme deficiency.
Frequently Asked Questions
Your Guide to Congenital Adrenal Hyperplasia
Got questions about congenital adrenal hyperplasia? You’re not alone.
We’ve compiled answers to some of the most common questions about CAH, including its causes, symptoms, diagnosis, treatment, and clinical trial participation. Still have questions? Contact our research team for more information. Call us at +1 (248) 721-9539 — we’ll be happy to assist you.
